Rio Rancho, NM — NTx Bio announced the launch of NTxscribe FLEX, a benchtop continuous-flow RNA production system designed for process development scientists, translational researchers and RNA therapeutic developers.
The company said NTxscribe FLEX extends its NTxscribe platform and uses the same patented continuous-flow, hollow fiber bioreactor architecture that powers its NTxscribe CORE system. The new system is designed to give researchers and development teams more direct control over RNA production, with customizable quantities and process parameters.
NTx Bio said traditional RNA production methods can be costly, time-consuming and difficult to scale, creating barriers for therapeutic programs before they reach clinical development. NTxscribe FLEX is intended to address those challenges with a research-use-only system designed to scale toward GMP material.
The system uses a fully closed continuous-flow process that integrates in vitro transcription through initial purification in a single automated run. The company said the approach enables controlled, scalable RNA production with minimal manual intervention.
While NTxscribe CORE is optimized for standardized, higher-volume production, NTxscribe FLEX is designed for customizability, allowing researchers and process development teams to adjust RNA output based on program needs. The system is built for compact, single-operator benchtop use and can integrate with upstream and downstream solutions.
“When we launched NTxscribe, we proved that continuous-flow RNA production could deliver speed, quality, and scalability that batch-based approaches simply can’t match. FLEX is the natural evolution of that platform and is designed for the scientists and organizations who are driving RNA therapeutics forward from the bench to the clinic,” said Joan Haab, Ph.D., CEO of NTx Bio. “By bringing our core technology into a more flexible, affordable and open format, we’re meeting a much broader range of customers where they are, whether that’s a process development team optimizing a new construct, a translational researcher working with complex RNA, or an emerging biotech building their RNA capabilities from the ground up. FLEX will be available as a GMP capable platform in early 2027 to ensure our RUO clients of today have the ability to scale into clinical phases and on to commercialization on a single platform.”
NTxscribe FLEX features automated RNA production from DNA template through initial purification; continuous-flow process control using HFBR architecture; support for longer and more complex RNA constructs; scalable process continuity from preclinical development through translational workflows; compact benchtop deployment; and customizable RNA output.
The system is designed to support RNA development workflows including therapeutic mRNA and saRNA development, personalized cancer vaccine programs, cell and gene therapy, process development and optimization, long and complex RNA constructs and CDMO technology evaluation.
